Table 1.
Participant characteristics by panela
| Variable | Overall N (%) |
|---|---|
| Number of participants | 101 |
| Age, median (quartile1, quartile 3); range | 48.0 (41, 56) (28–78) |
| Sex | |
| Male | 56 (55.4) |
| Female | 45 (44.6) |
| Role | |
| Chair | 8 (7.9) |
| Methodologist | 16 (15.8) |
| Clinician | 66 (65.4) |
| Patient representatives | 11 (10.9) |
| Panel | |
| Anticoagulation | 13 (12.9) |
| Cancer | 15 (14.9) |
| Heparin-induced thrombocytopenia | 11 (10.9) |
| Immune thrombocytopenia | 16 (15.8) |
| Pediatric | 15 (14.9) |
| Pregnancy | 10 (9.9) |
| Thrombophilia | 7 (6.9) |
| Treatment | 14 (13.9) |
| Country of origin | |
| United States | 52 (51.5) |
| Canada | 25 (24.8) |
| Netherlands | 5 (5.0) |
| Italy | 3 (3.0) |
| United Kingdom | 3 (3.0) |
| Germany | 3 (3.0) |
| Australia | 3 (3.0) |
| Austria | 2 (2.0) |
| Argentina | 1 (1.0) |
| Belgium | 1 (1.0) |
| Denmark | 1 (1.0) |
| New Zealand | 1 (1.0) |
| Switzerland | 1 (1.0) |
| Years of experienceb, median (quartile 1, quartile 3); (range) | 18 (11,26) (2–49) |
| Self-reported level of experienceb | |
| Higher than others | 46 (55.4) |
| About same as others | 32 (38.6) |
| Lower than others | 5 (6.0) |
| How many patients with similar condition do you treat per monthb | |
| None | 13 (16.3) |
| 1–5 | 14 (17.5) |
| 6–10 | 3 (3.8) |
| 11–15 | 7 (8.8) |
| More than 15 | 43 (53.8) |
a
Included in the final analysis; there was no statistically significant difference between these participants and those that were excluded from the analysis (see Fig 1).
b
Questions regarding professional experience were only answered by clinicians.